DBV Technologies Stock Forecast, Price & News

-0.03 (-0.55 %)
(As of 07/30/2021 11:31 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume200 shs
Average Volume357,462 shs
Market Capitalization$593.02 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive DBVT News and Ratings via Email

Sign-up to receive the latest news and ratings for DBV Technologies and its competitors with MarketBeat's FREE daily newsletter.

DBV Technologies logo

About DBV Technologies

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in 4 to 11 years of age children, adolescents, and adults. The company is also developing Viaskin Milk that is in Phase I/II clinical trial for the treatment of Immunoglobulin E (IgE) mediated cow's milk protein allergy (CMPA) and milk-induced eosinophilic esophagitis; Viaskin Egg, a pre-clinical stage product for the treatment of hen's egg allergy; and booster vaccine for Bordetella pertussis. Its other earlier stage research programs include a vaccine for the respiratory syncytial virus, as well as treatments for Crohn's disease, celiac disease, and type I diabetes. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was founded in 2002 and is headquartered in Montrouge, France.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.92 out of 5 stars

Medical Sector

656th out of 2,216 stocks

Biological Products, Except Diagnostic Industry

101st out of 213 stocks

Analyst Opinion: 3.3Community Rank: 3.2Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

DBV Technologies (NASDAQ:DBVT) Frequently Asked Questions

Is DBV Technologies a buy right now?

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for DBV Technologies in the last year. There are currently 3 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" DBV Technologies stock.
View analyst ratings for DBV Technologies
or view top-rated stocks.

What stocks does MarketBeat like better than DBV Technologies?

Wall Street analysts have given DBV Technologies a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but DBV Technologies wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is DBV Technologies' next earnings date?

DBV Technologies is scheduled to release its next quarterly earnings announcement on Monday, August 2nd 2021.
View our earnings forecast for DBV Technologies

How can I listen to DBV Technologies' earnings call?

DBV Technologies will be holding an earnings conference call on Monday, August 2nd at 5:00 PM Eastern. Interested parties can register for or listen to the call using this link.

How were DBV Technologies' earnings last quarter?

DBV Technologies S.A. (NASDAQ:DBVT) issued its earnings results on Monday, May, 3rd. The company reported ($0.27) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.39) by $0.12. The business had revenue of $2.94 million for the quarter.
View DBV Technologies' earnings history

How has DBV Technologies' stock price been impacted by COVID-19 (Coronavirus)?

DBV Technologies' stock was trading at $7.08 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, DBVT stock has decreased by 23.9% and is now trading at $5.39.
View which stocks have been most impacted by COVID-19

What price target have analysts set for DBVT?

7 brokers have issued 12 month target prices for DBV Technologies' stock. Their forecasts range from $2.00 to $14.00. On average, they expect DBV Technologies' share price to reach $6.70 in the next twelve months. This suggests a possible upside of 24.3% from the stock's current price.
View analysts' price targets for DBV Technologies
or view top-rated stocks among Wall Street analysts.

Who are DBV Technologies' key executives?

DBV Technologies' management team includes the following people:
  • Mr. Daniel Tassé, CEO & Director (Age 61, Pay $1.1M)
  • Mr. Sébastien Robitaille, Chief Financial Officer (Age 51, Pay $291.82k)
  • Dr. Pharis Mohideen, Chief Medical Officer (Age 56, Pay $625.26k)
  • Dr. Pierre-Henri Benhamou, Co-Founder & Member of Scientific Advisory Board (Age 66)
  • Mr. Pascal Wotling, Chief Technical Operations Officer
  • Anne Pollak, Head of Investor Relations
  • Ms. Michele F. Robertson, Chief Legal Officer
  • Joseph Becker, VP of Global Corp. Communications
  • Ms. Caroline Daniere, Chief HR Officer & Chief of Staff (Age 46)
  • Dr. Wence Agbotounou, Chief Clinical Trial Officer & Sr. VP

Who are some of DBV Technologies' key competitors?

What other stocks do shareholders of DBV Technologies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other DBV Technologies investors own include Aimmune Therapeutics (AIMT), OPKO Health (OPK), Bellicum Pharmaceuticals (BLCM), Axsome Therapeutics (AXSM), Gilead Sciences (GILD), Novavax (NVAX), AbbVie (ABBV), Pieris Pharmaceuticals (PIRS), Pfizer (PFE) and Sangamo Therapeutics (SGMO).

What is DBV Technologies' stock symbol?

DBV Technologies trades on the NASDAQ under the ticker symbol "DBVT."

How do I buy shares of DBV Technologies?

Shares of DBVT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is DBV Technologies' stock price today?

One share of DBVT stock can currently be purchased for approximately $5.39.

How much money does DBV Technologies make?

DBV Technologies has a market capitalization of $593.02 million and generates $11.28 million in revenue each year. The company earns $-159,550,000.00 in net income (profit) each year or ($1.26) on an earnings per share basis.

How many employees does DBV Technologies have?

DBV Technologies employs 104 workers across the globe.

What is DBV Technologies' official website?

The official website for DBV Technologies is

Where are DBV Technologies' headquarters?

DBV Technologies is headquartered at 177-181 AVENUE PIERRE BROSSOLETTE, MONTROUGE I0, 92120.

How can I contact DBV Technologies?

DBV Technologies' mailing address is 177-181 AVENUE PIERRE BROSSOLETTE, MONTROUGE I0, 92120. The company can be reached via phone at 33-1-55-42-78-78 or via email at [email protected]

This page was last updated on 7/30/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.